DCN Dx

DCN Dx is a biotechnology startup founded in 2005, headquartered in the United States, that specializes in the contract development of rapid point of care tests. The company's slogan, "Diagnostic Product Development for Every Application," reflects its commitment to offering a wide range of services and products tailored to assist clients in the design and development of user-centric, high-performing diagnostic devices. At the core of DCN Dx's offerings is the contract development of rapid immunoassays, with a focus on lateral flow, flow through, and microfluidic formats. The company's ISO 9001:2015 compliant development process integrates assay and device development pathways closely, ensuring the best chance of commercial success for the product. Additionally, its integrated engineering team works closely with scientists to design, develop, and integrate entire devices, delivering comprehensive solutions to clients. In addition to custom product development, DCN Dx provides various products and services to assist clients at any stage of development, including custom education and training courses, consulting services, and material starter kits for rapid assay development. The company's comprehensive offerings position it as a single source for managing and delivering fully validated assay platforms. Notably, DCN Dx secured a Private Equity Round investment on 19 November 2020 with Martis Capital as the investor, signifying a significant milestone in its growth and development. With its focus on innovation and client-centered solutions in the biotechnology industry, DCN Dx presents an attractive investment opportunity for venture capital firms seeking exposure to the rapidly evolving diagnostics market. For more information, visit www.dcndx.com or contact [email protected] or (760) 804-3886.